MORE safety concerns with dronedarone (Multaq)

See the December 2011 completed FDA safety review of Multaq (dronedarone)

There are MORE safety concerns with dronedarone (Multaq).

This time it has to do with the TYPE of atrial fibrillation.

Multaq improves CV outcomes in some patients with PAROXYSMAL or PERSISTENT atrial fib. These resolve spontaneously or with cardioversion.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote